Metrovacesa (XMAD:MVC) Other Long-Term Liabilities: €21.5 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:MVC Metrovacesa SA XMAD:MVC
79 GF Score
Price €11.08
GF Value €10.76
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Metrovacesa Other Long-Term Liabilities?

Metrovacesa XMAD:MVC +0.73% 79 Other Long-Term Liabilities is €21.5 Mil as of Dec. 2025. GuruFocus rates XMAD:MVC with a GF Score™ of 79/100 and a GF Value™ of €10.76 (Fairly Valued). The stock has 5 warning signs investors should review.

Metrovacesa's other long-term liabilities for the quarter that ended in Dec. 2025 was €21.5 Mil.

Metrovacesa's quarterly other long-term liabilities increased from Dec. 2024 (€18.2 Mil) to Jun. 2025 (€20.8 Mil) and increased from Jun. 2025 (€20.8 Mil) to Dec. 2025 (€21.5 Mil).

Metrovacesa's annual other long-term liabilities declined from Dec. 2023 (€23.2 Mil) to Dec. 2024 (€18.2 Mil) but then increased from Dec. 2024 (€18.2 Mil) to Dec. 2025 (€21.5 Mil).

Metrovacesa Other Long-Term Liabilities Related Terms

Metrovacesa Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Metrovacesa's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metrovacesa Other Long-Term Liabilities Chart

Metrovacesa Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.21 20.98 23.16 18.23 21.50

Metrovacesa Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.16 25.22 18.23 20.78 21.50
XMAD:MVC
79GF Score
Metrovacesa SA XMAD:MVC
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metrovacesa Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €21.5 Mil mean?
Metrovacesa (XMAD:MVC) has a Other Long-Term Liabilities of €21.5 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Metrovacesa and its competitors.
Is Metrovacesa's Other Long-Term Liabilities too high?
Metrovacesa's current Other Long-Term Liabilities is €21.5 Mil. Overall, Metrovacesa has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metrovacesa's Other Long-Term Liabilities compare to competitors?
Metrovacesa's Other Long-Term Liabilities of €21.5 Mil can be compared against companies in the Real Estate industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Real Estate company?
A good Other Long-Term Liabilities depends on the Real Estate industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Metrovacesa and its competitors. Metrovacesa's current Other Long-Term Liabilities is €21.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metrovacesa stock overvalued right now?
Based on GuruFocus' analysis, Metrovacesa (XMAD:MVC) is currently considered Fairly Valued. The stock's GF Value™ is €10.76, compared to a current price of €11.08 — trading 3% above its estimated fair value. The current Other Long-Term Liabilities is €21.5 Mil. Metrovacesa's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Metrovacesa (XMAD:MVC), the current Other Long-Term Liabilities is €21.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Metrovacesa (XMAD:MVC) Overvalued in 2026?

Based on GuruFocus' analysis, Metrovacesa stock appears to be overvalued. The current stock price of €11.08 is trading 3% above its estimated GF Value™ of €10.76. GuruFocus considers Metrovacesa to be Fairly Valued.

Key valuation signals for XMAD:MVC:

  • Other Long-Term Liabilities: €21.5 Mil
  • GF Value™: €10.76 vs. price of €11.08 (3% above fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the XMAD:MVC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Metrovacesa Business Description

Other Exchanges MVCe:UK0HXI:UKMS6N:Germany
Address C/ Puerto de Somport, 23, edificio A, Planta 1, Madrid, ESP, 28050
Metrovacesa SA is a real estate company. Its operations mainly focus on the development and sale of residential property on land classified as suitable for development. Its operating segments are Residential, Commercial, and Others. The company earns the majority of its revenue through the Residential segment. Geographically, it operates majorly in Spain.
79GF Score

Get the complete analysis for XMAD:MVC

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.08
Price
€10.76
GF Value